drugset
drugset / Trial / NCT04746287

Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects

NCT04746287 ↗

Phase 1 Completed 87 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a first-in-human study of CKD-510 in single-ascending dose and multiple-ascending dose in healthy subjects. This trial is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics of food effects of CKD-510.

Timeline

Start
2020-01-14
Primary completion
2021-08-24
Completion
2021-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-510 Unknown — —

Indications

No indication recorded.